Delfina Costa, Debora Russo, Serena Vella, Claudio Russo, Alessandro Poggi, Antonella Brizzolara, Ilaria Penna, Andrea Mescola, Paola Menichini, Tullio Florio, Antonio Daga, Claudio Canale, Aldo Pagano, Arianna Gigoni, Federico Villa, and Mario Nizzari
// Ilaria Penna 1, 3, * , Arianna Gigoni 1, 3, * , Delfina Costa 1, 3, * , Serena Vella 4, * , Debora Russo 3 , Alessandro Poggi 3 , Federico Villa 1, 3 , Antonella Brizzolara 1, 3 , Claudio Canale 5 , Andrea Mescola 5 , Antonio Daga 3 , Claudio Russo 6 , Mario Nizzari 2 , Tullio Florio 2, 7 , Paola Menichini 3 , Aldo Pagano 1, 3 1 Department of Experimental Medicine (DIMES), University of Genova, Genova, Italy 2 Department of Internal Medicine (DIMI), University of Genova, Genova, Italy 3 IRCCS-AOU San Martino-IST, Genova, Italy 4 Department of Laboratory Medicine and Advanced Biotechnologies, IRCCS-ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione), Palermo, Italy 5 Nanophysics Unit, Italian Institute of Technology, Morego, Genova, Italy 6 Department of Health Sciences, University of Molise, Campobasso, Italy 7 Center of Excellence for Biomedical Research (CEBR), University of Genova, Genova, Italy * These authors have contributed equally to this work Correspondence to: Aldo Pagano, email: aldo.pagano@unige.it Keywords: neuroblastoma, non-coding RNA, GTSE1, tumorigenesis, metastasis Received: March 04, 2016 Accepted: November 23, 2016 Published: December 24, 2016 ABSTRACT We recently reported the in vitro over-expression of 45A, a RNA polymerase III-transcribed non-coding (nc)RNA, that perturbs the intracellular content of FE65L1 affecting cell proliferation rate, short-term response to genotoxic stress, substrate adhesion capacity and, ultimately, increasing the tumorigenic potential of human neuroblastoma cells. In this work, to deeply explore the mechanism by which 45A ncRNA contributes to cancer development, we targeted in vitro and in vivo 45A levels by the stable overexpression of antisense 45A RNA. 45A downregulation leads to deep modifications of cytoskeleton organization, adhesion and migration of neuroblastoma cells. These effects are correlated with alterations in the expression of several genes including GTSE1 (G2 and S phase-expressed-1), a crucial regulator of tumor cell migration and metastatic potential. Interestingly, the downregulation of 45A ncRNA strongly affects the in vivo tumorigenic potential of SKNBE2 neuroblastoma cells, increasing tumor nodule compactness and reducing GTSE1 protein expression in a subcutaneous neuroblastoma mouse model. Moreover, intracardiac injection of neuroblastoma cells showed that downregulation of 45A ncRNA also influences tumor metastatic ability. In conclusion, our data highlight a key role of 45A ncRNA in cancer development and suggest that its modulation might represent a possible novel anticancer therapeutic approach.